Imfinzi-Based Regimen Reduced the Risk of Death by 22% in Early Gastric Cancer vs. Chemotherapy Alone in Matterhorn Phase III Trial
October 18, 2025
October 18, 2025
WILMINGTON, Delaware, Oct. 18 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
IMFINZI (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
More than two thirds of patients treated with IMFINZI-based perioperative regimen were alive at three years
First and only perioperative immunotherapy approach to show survival benefit in . . .
* * *
IMFINZI (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
More than two thirds of patients treated with IMFINZI-based perioperative regimen were alive at three years
First and only perioperative immunotherapy approach to show survival benefit in . . .